- Report
- March 2025
Global
From €4301EUR$4,900USD£3,742GBP
- Report
- February 2025
- 100 Pages
Global
From €5223EUR$5,950USD£4,544GBP
- Report
- February 2026
- 575 Pages
Global
From €5135EUR$5,850USD£4,467GBP
- Report
- February 2026
- 382 Pages
Global
From €5135EUR$5,850USD£4,467GBP
- Report
- January 2026
- 190 Pages
Global
From €3458EUR$3,939USD£3,008GBP
- Report
- January 2026
- 195 Pages
Global
From €3458EUR$3,939USD£3,008GBP
- Report
- January 2026
- 183 Pages
Global
From €3458EUR$3,939USD£3,008GBP
- Report
- January 2026
- 182 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- January 2026
- 180 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- January 2026
- 181 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- January 2026
- 181 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- January 2026
- 185 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- January 2026
- 185 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- January 2026
- 180 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- January 2026
- 180 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- November 2025
- 185 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- February 2025
- 185 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- February 2025
- 184 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- January 2026
- 181 Pages
Global
From €3950EUR$4,500USD£3,437GBP
- Report
- January 2026
- 186 Pages
Global
From €3950EUR$4,500USD£3,437GBP

Circulating Tumor DNA (ctDNA) is a type of genetic material found in the bloodstream of cancer patients. It is a valuable tool for cancer diagnosis, prognosis, and treatment. ctDNA can be used to detect the presence of cancer, identify the type of cancer, and monitor the progression of the disease. It can also be used to detect mutations in cancer cells, which can help guide treatment decisions.
ctDNA is a rapidly growing field in genomics, with many companies developing technologies to detect and analyze ctDNA. These companies are developing technologies such as next-generation sequencing, digital PCR, and microfluidics to detect and analyze ctDNA. Companies are also developing technologies to detect and analyze ctDNA in real-time, allowing for more accurate and timely diagnosis and treatment.
Some companies in the ctDNA market include Illumina, Thermo Fisher Scientific, QIAGEN, Bio-Rad Laboratories, and Guardant Health. Show Less Read more